Asset Details
Do you wish to reserve the book?
Nanoparticulation of Prodrug into Medicines for Cancer Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nanoparticulation of Prodrug into Medicines for Cancer Therapy
Do you wish to request the book?
Nanoparticulation of Prodrug into Medicines for Cancer Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nanoparticulation of Prodrug into Medicines for Cancer Therapy
2021
Overview
This article provides a broad spectrum about the nanoprodrug fabrication advances co‐driven by prodrug and nanotechnology development to potentiate cancer treatment. The nanoprodrug inherits the features of both prodrug concept and nanomedicine know‐how, attempts to solve underexploited challenge in cancer treatment cooperatively. Prodrugs can release bioactive drugs on‐demand at specific sites to reduce systemic toxicity, this is done by using the special properties of the tumor microenvironment, such as pH value, glutathione concentration, and specific overexpressed enzymes; or by using exogenous stimulation, such as light, heat, and ultrasound. The nanotechnology, manipulating the matter within nanoscale, has high relevance to certain biological conditions, and has been widely utilized in cancer therapy. Together, the marriage of prodrug strategy which shield the side effects of parent drug and nanotechnology with pinpoint delivery capability has conceived highly camouflaged Trojan horse to maneuver cancerous threats. Prodrugs release bioactives on‐demand at diseased sites to reduce systemic toxicity of parent drugs; the nanotechnology formulate the prodrug into nanosized. Their marriage boosts an emerging and effective solution to cancerous implications and beyond. The nanoprodrug inherits the features of both prodrug concept and nanomedicine expertise, attempting to address unmet needs in cancer treatment cooperatively.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
